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Abstract: Mass spectrometry imaging (MSI) is a powerful tool to visualize the spatial distribution
of molecules on a tissue section. The main limitation of MALDI-MSI of proteins is the lack of direct
identification. Therefore, this study focuses on a MSI~LC-MS/MS-LF workflow to link the results
from MALDI-MSI with potential peak identification and label-free quantitation, using only one tissue
section. At first, we studied the impact of matrix deposition and laser ablation on protein extraction
from the tissue section. Then, we did a back-correlation of the m/z of the proteins detected by
MALDI-MSI to those identified by label-free quantitation. This allowed us to compare the label-free
quantitation of proteins obtained in LC-MS/MS with the peak intensities observed in MALDI-MSI.
We managed to link identification to nine peaks observed by MALDI-MSI. The results showed that the
MSI~LC-MS/MS-LF workflow (i) allowed us to study a representative muscle proteome compared
to a classical bottom-up workflow; and (ii) was sparsely impacted by matrix deposition and laser
ablation. This workflow, performed as a proof-of-concept, suggests that a single tissue section can be
used to perform MALDI-MSI and protein extraction, identification, and relative quantitation.
Keywords: MALDI mass spectrometry imaging; protein identification; label-free quantitation;
skeletal muscle
1. Introduction
MALDI mass spectrometry imaging (MALDI-MSI) allows analyzing the spatial distribution of
a wide variety of molecules simultaneously within a single tissue section [1]. MALDI-MSI is widely
used to study biological phenomena thanks to its capability to map hundreds of molecules without
any labeling, and in a single acquisition sequence. Previous investigations based on human biopsies
indicated that muscle aging (sarcopenia) is associated with important modifications at the fiber-type
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level. Specifically, MALDI-MSI provided evidence for aging- and metabolic syndrome-dependent
alterations in intra-myofibrillar lipids [2]. Using small human biopsies, MSI of proteins could be less
sample-consuming than usual analytical techniques, such as two-dimensional gel electrophoreses [3]
or shot-gun proteomics [4]. However, the main limitation of MALDI-MSI of proteins is the lack
of direct identification, and therefore we need an additional step to overcome this issue [5].
Three strategies based on mass spectrometry methods allow protein identification: top-down and
bottom-up experiments directly on tissue sections, and indirect identification approaches.
Bottom-up experiments on tissue sections consist of the tryptic digestion of proteins in spatially
discrete regions followed by MALDI-MSI with MS/MS analysis [6]. However, on-tissue digestion
of proteins may lead to partial diffusion of the resulting peptides and thus to miss-interpreting in
situ protein localization [7,8]. Moreover, identifying proteins directly from tissues using MS/MS
experiments for proteins or peptides is hampered by the low sensitivity caused by ion-suppression
effects due to the complex molecular composition of tissues [5]. In addition, each protein analyzed by
MALDI mass spectrometry results in a singly charged state ion, and ion activation by MALDI fails
to produce fragmentation and identification. Protein sequence information could be achieved using
MALDI In-Source Decay (ISD) mass spectrometry directly on tissue sections [9]. However, obtaining the
protein sequence information by MALDI-ISD mass spectrometry is challenging in the case of protein
mixtures [10]. Some studies focused on on-tissue tryptic digestion followed by micro-extraction [11]
and on spatially directed micro-extraction of intact proteins [12] to identify proteins from specific
locations in tissue. These strategies succeeded in identifying proteins from tissue sections, but their
limitation lies in the need for at least a second tissue section for protein or peptide extraction.
Indirect identification approaches can be used to overcome these issues. These strategies are
based on matching MALDI-MSI data with data generated using independent experiments, such as
LC-MS/MS bottom-up approaches. Back-correlation of the m/z resulting from the off-tissue identified
proteins to those of the proteins detected by MALDI-MSI is still a manual process, during which
great care must be taken. Indeed, according to the mass tolerance window, thousands of possible
proteins could match theoretically. Precautions must be taken, and additional validation might be
necessary. Maier et al. [13] developed a method for the extraction and the identification of proteins
embedded in the MALDI matrix layer, based on the principle that any MALDI-MSI biomarker must
be contained in the MALDI matrix layer to be detectable by the mass spectrometer. This strategy
has the great advantage to study the same set of proteins, both in MALDI-MSI and LC-MS/MS,
after in situ extraction, and thus it reduces the risk of mistakes in protein identification. Thanks to
this approach, these authors developed a publically available database, based on the identification
of proteins extracted on matrix-coated tissue sections. Recently, Spraggins et al. [14] published
a proof-of-concept study based on MALDI-FTICR-MSI of intact proteins linked with proteomic
data obtained by LC-MS/MS. The use of high mass accuracy allowed them to identify proteins
and protein modifications.
Nonetheless, to our knowledge, there is little information in the literature about the validation of
the relative quantitation of proteins in MALDI-MSI. Different kinds of strategies at different tissue
scales have been developed. At the biopsy scale, localized proteomic profiles and an overlay of the
protein’s expression heat map on a tissue/biopsy were performed to give a relative quantitation of
proteins within the tissue [15]. Another strategy consists of the quantitation-based mass spectrometry
imaging of proteins by parafilm-assisted micro-dissection [16] at the tissue scale.
In our study, a workflow linking results from MALDI-MSI with potential protein identification
and their relative label-free quantitation was developed. For this, we combined MALDI-MSI on
a muscle section, protein extraction from the same section, their identification by LC-MS/MS, and then
a back-correlation between label-free quantitation and peak intensities observed in MALDI-MSI.
At first, we studied the impact of matrix deposition and laser ablation on protein extraction from
tissue sections. Indeed, the MALDI procedure occurring during MSI acquisition might impact the
extractability of proteins and thus the back-correlation between imaging and potential identification.
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Then, we did a back-correlation of the m/z of the off-tissue identified proteins by LC-MS/MS to
those of the proteins detected by MALDI-MSI. This allowed us to compare the label-free quantitation
of proteins based on peptide intensities with the proteins peak intensities observed in MALDI-MSI.
This proof-of-concept was thus developed to study protein quantitation on a muscle section with
the final objective of being used with regioselectivity. Finally, we validated and demonstrated the
suitability of this workflow for the analysis of human muscle biopsies at the fiber-type level.
2. Materials and Methods
2.1. Experiment Summary
The experimental workflow is described in Figure 1. For each of the eight individuals, serial muscle
biopsy cross-sections were performed. Proteins were extracted directly on the section (‘On Tissue’),
after matrix deposition (‘SA-coated’), and after spectra acquisition (‘Post-MSI’), and from the
homogenization of 10 consecutive muscle sections (‘Muscle homogenate’). All extracts were hydrolyzed
by trypsin, and the peptides were analyzed by LC-MS/MS. Proteins lists were compared to evaluate
the impact of matrix deposition and laser ablation on protein extractability, and to evaluate how
the extraction from the ‘Post-MSI’ is representative of the ‘Muscle homogenate’ reference approach.
At last, back-correlation of m/z of ‘Post-MSI’ proteins to those of the proteins detected by MALDI-MSI,
was performed to compare the label-free quantitation of ‘Post-MSI’ proteins with the peak intensities
of MALDI-MSI proteins.
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2.2. Reagents
All reagents were of the highest a aila le ra e. ater used in all experiments was purified by
a Milli-Q system (Millipore, Milford, MA, USA). Acetonitrile and HPLC-grade methanol were purchased
from Biosolve B. V. (Valkensvaard, Netherlands). Ammonium bicarbonate, ethanol, DL-dithiothreitol,
iodoacetamide, isopentane, trifluoroacetic acid, urea, thiourea, CHAPS, protease inhibitor cocktail,
and sinapinic acid (SA) were from Sigma (Saint-Quentin Fallavier, France). Sequencing grade modified
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porcine trypsin (V5111) was purchased from Promega (Charbonnières, France). Protein calibration
standard was from Bruker Daltonics (Bremen, Germany). C18 Spin Tubes, and Agilent Peptide Cleanup
were purchased from Agilent Technologies (Wilmington, DE, USA).
2.3. Subjects and Tissue Preparation
Our study included eight healthy young men (age 25 years) selected from Saint-Etienne University.
They all underwent standard medical examination, and performed a maximal exercise stress before
their inclusion in the study. The study was approved by the local Ethical Committee (ClinicalTrials.gov
Identifier: NCT00759304), and all subjects provided written informed consent for participation.
Needle biopsies were taken under local anesthesia from the right vastus lateralis muscle, after overnight
fasting. Biopsies were mounted with tissue freezing medium, cryofixed in isopentane (−160 ◦C) cooled
on liquid nitrogen and stored at −80 ◦C. Serial cross-sections (10 µm thick, 10 mm2) were performed
using a cryostat (Microm, Francheville, France) at −20 ◦C.
2.4. MALDI Mass Spectrometry Imaging
For MALDI-MSI, sections were collected on conductive indium-tin-oxide glass slides
(Bruker Daltonics, Bremen, Germany). Muscle sections were subjected to washing steps using 70% and
95% Ethanol to deplete lipids, and were dried in a desiccator for 30 min. The matrix was applied using
the ImagePrep station (Bruker Daltonics) according to the protocol detailed in Table 1. The matrix was
10 mg/mL sinapinic acid in water/acetonitrile 60:40 (v/v) with 0.2% trifluoroacetic acid.
Table 1. Individual ImagePrep phase settings for sinapinic acid (10 mg/mL in 60% ACN and 0.2%
TFA) deposition onto tissue sections.
Phase Sensor Nebulization Incubation Drying
1 15 cycles 25% ± 30% power with fixedspray time of 2.2 s 15 s 50 s
2 0.1 V within5–10 cycles
25% ± 30% power with 0.05 V
sensor controlled spray time
30 s ± 30 s
Complete dry every cycle,
safe dry 20 s
3 0.1 V within6–18 cycles
25% ± 30% power with 0.10 V
sensor controlled spray time
Grade 20% ± 60% complete dry
every 2 cycles, safe dry 20 s
4 0.3 V within12–40 cycles
25% ± 30% power with 0.2 V
sensor controlled spray time
Grade 20% ± 60% complete dry
every 4 cycles, safe dry 50 s
5 0.35 V ± 0.30 V,within 12–64 cycles
25% ± 35% power with 0.3 V
sensor controlled spray time
Grade 20% ± 60% complete dry
every 4 cycles, safe dry 60 s
The MALDI spectra were acquired on an Autoflex Speed MALDI-TOF/TOF mass spectrometer
with a Smartbeam laser using FlexControl 3.4 and FlexImaging 3.0 software packages
(Bruker Daltonics). For protein imaging, ions were detected in positive linear mode at a mass range
of m/z 2000–20,000 with a sampling rate of 0.63 GS/s. The lateral resolution was set to 100 µm and
a total of 500 laser shots were accumulated per pixel at constant laser power. Deflection was set at
m/z of 1500, and laser focus at medium. Analysis were performed using a detector gain of 2.783 V,
ion source voltage 1 at 19.5 kV, ion source voltage 2 at 18.15 kV and lens voltage at 7 kV. A protein
standard (Bruker Daltonics, Bremen, Germany) was employed for external calibration of spectra,
which was done externally on the same target before each measurement.
2.5. ‘On Tissue’, ‘SA-Coated’, and ‘Post-MSI’ Sample Preparation
Proteins were extracted on serial muscle biopsy cross-sections: directly on tissue sections
(‘On Tissue’), on matrix-coated muscle tissue (‘SA-coated’ for Sinapinic Acid), and on the sections
used for MALDI-MSI measurements (‘Post-MSI’), using a method derived from Maier et al. [13].
Each experiment was repeated twice for each individual. For ‘On Tissue’, ‘SA-coated’, and ‘Post-MSI’
sections, the sample area was covered with 2 µL of 7.5% acetonitrile in 0.2% trifluoroacetic acid,
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and incubated for 1 min. The liquid containing the protein extract was collected, and this extraction was
repeated once. The same area was then covered with 1 µL of 60% acetonitrile in 0.2% trifluoroacetic acid
and the liquid containing the protein extract was immediately collected and combined with previous
extracts (5 µL total). Protein extracts were reduced with 20 µL of 10 mM dithiotreitol in 50 mM
ammonium bicarbonate (pH = 8), during 15 min at 55 ◦C. After cooling, alkylation was performed by
adding 20 µL of 100 mM iodoacetamide in 50 mM ammonium bicarbonate, during 15 min at 20 ◦C in
darkness. After neutralization, protein digestion was achieved by adding 25 µL of trypsin solution
(20 ng/µL) in 50 mM ammonium bicarbonate, and overnight incubation at 37 ◦C.
Trypsin digestion was stopped with 2% trifluoroacetic acid, and after 5 min centrifugation
at 3000× g, the supernatant was collected. The pellet was washed using 2% acetonitrile,
0.05% trifluoroacetic acid in water, sonicated for 5 min, centrifuged during 5 min at 3000× g, and the
supernatant was collected and combined with the previous one, resulting in 100 µL samples.
2.6. ‘Muscle Homogenate’ Preparation
For ‘muscle homogenate’ experiments, 10 cross-sections were homogenized at 4 ◦C in a solubilization
buffer containing 8.3 M urea, 2 M thiourea, 2% CHAPS, 1% dithiothreitol and protease inhibitor
cocktail, and centrifuged for 10 min at 10,000× g. The supernatant was mixed with 1 volume 2% SDS,
5% β-mercaptoethanol, 10% glycerol and 62 mM Tris-HCl, pH 6.8, and heated at 95 ◦C for 5 min.
SDS-PAGE (12% acrylamide) was performed using a Mini-Protean II electrophoresis unit (BioRad,
Marnes-La-Coquette, France). Samples were loaded at 20 µg protein per lane. To concentrate the
samples, gels were run at 100 V until the dye front reached the bottom of the concentration gel.
Gels were fixed with 30% ethanol, 5% acetic acid, and stained overnight in Coomassie brilliant blue
G-250. Excised lanes were reduced with 10 mM dithiotreitol, alkylated with 55 mM iodoacetamide
(both in 50 mM ammonium bicarbonate), and incubated in 25 mM ammonium bicarbonate with
acetonitrile (v/v) until destaining. After incubation in 100% acetonitrile, gel pieces were dried in
a vacuum SpeedVac. They were further rehydrated with 30 µL of a trypsin solution (10 ng/µL in 25 mM
ammonium bicarbonate), and finally incubated overnight at 37 ◦C. Peptide extraction was optimized
by adding 24 µL of acetonitrile 100% followed by 10 min of sonication. The trypsin digests were dried
in a vacuum SpeedVac and stored at −20 ◦C in a solution of 2% acetonitrile, 0.05% trifluoroacetic acid
before LC-MS/MS analysis.
2.7. LC-MS/MS Sample Preparation, Data Acquisition, Database Search and Protein Identification
‘On Tissue’, ‘SA-coated’, ‘Post-MSI’ and ‘Muscle homogenate’ samples were desalted using C18
Spin Tubes (Agilent Peptide Cleanup, Agilent Technologies, Wilmington, DE, USA), according to the
manufacturer’s instructions. Briefly, the resin was wet using 200 µL of 50% acetonitrile, the tubes were
centrifuged at 1500 g for 1 min, and this step was repeated once. The resin was then equilibrated
with 200 µL of 0.5% trifluoroacetic acid in 5% acetonitrile, tubes were centrifuged at 1500 g for 1 min,
and this step was repeated once. Samples were then loaded on the resin, and the resin was washed
three times using 200 µL of 0.5% trifluoroacetic acid in 5% acetonitrile. Samples were eluted using
20 µL of 70% acetonitrile with 0.1% trifluoroacetic acid, dried and resuspended in 0.05% trifluoroacetic
acid for mass spectrometry analysis.
For Nano-LC-ESI-MS/MS analysis, peptides mixtures were analyzed in duplicate by online
nanoflow liquid chromatography using the Ultimate 3000 RSLC (Dionex, Voisins le Bretonneux,
France) with nanocapillary columns of 25 cm length × 75 µm I.D., 3 µm, 100Å (Acclaim PepMap100
C18, Dionex, Thermo Fisher Scientific, Waltham, MA, USA). The solvent gradient increased linearly
from 4% to 50% acetonitrile in 0.5% formic acid at a flow rate of 200 nL/min for 100 min. The elute
was electrosprayed in positive-ion mode at 2.7 kV in a LTQ-VELOS mass spectrometer (Thermo Fisher
Scientific, Courtaboeuf, France) through a nanoelectrospray ion source which was operated in a CID
top 10 mode (i.e., one full scan MS and the 10 major peaks in the full scan were selected for MS/MS).
Full-enhanced-scan MS spectra were acquired with one microscan (m/z 400–1600). Dynamic exclusion
Proteomes 2016, 4, 32 6 of 16
was used with two repeat counts, 15 s repeat duration and 45 s exclusion duration. For MS/MS,
isolation width for ion precursor was fixed at 2 m/z, single charged species were rejected; fragmentation
used 37% normalized collision energy and a default activation of 0.250.
Thermo Proteome Discoverer v1.3 (Thermo Fisher Scientific, Waltham, MA, USA) was used for
raw data file processing, and MASCOT was used for database search (http://www.matrixscience.com).
For protein identification, the Uniprot Taxonomy Human (01/10/2013, 84,843 sequences) protein
database was used. The following parameters were considered for the searches: peptide mass tolerance
was set to 500 ppm, fragment mass tolerance was set to 0.5 Da and a maximum of two missed cleavages
was allowed. Variable modifications were methionine oxidation (M) and carbamidomethylation (C)
of cysteine. Protein identification was considered valid if at least one peptide with a statistically
significant Mascot score assigned it (with Mascot score ≥ 36 for p-value < 0.05 with a False Discovery
Rate (FDR) at 1%). Identification of proteins based on one peptide was accepted after checking the
correct assignment of fragment ion matches (at least three consecutive fragments b/y, match peaks
well above the background noise). Identifications not satisfying these defined criteria were rejected.
2.8. Label-Free Protein Quantitation
The spectra (Thermo raw files) acquired for ‘Post-MSI’ samples were loaded into the Progenesis QI
software (version 1.0, Nonlinear Dynamics, Newcastle, UK) and label-free quantitation was performed
as described by Theron et al. [4]. Briefly, for each sample, the profile data of the MS scans and
MS/MS spectra were converted to peak lists comprising m/z and abundance with Progenesis QI using
a proprietary algorithm. One sample was automatically set as the reference, and the retention times of
all other samples were automatically aligned to create maximal overlay of the two-dimensional feature
maps. Features with only one charge, with retention time windows lower than 6 s or with retention time
lower than 20 min and higher than 80 min were excluded from further analyses. Using all remaining
features, a normalization factor was calculated for each sample, to correct experimental variation.
All unique validated peptides (with Mascot score ≥ 36 for p-value < 0.05) of an identified protein
were included for quantification, and the total cumulative abundance was calculated by summing
the abundances of all peptides allocated to the respective protein. Analysis was performed using the
normalized abundances across all runs.
2.9. MALDI Data Analysis
Spectra from each imaging sequence were baseline-subtracted (TopHat) and smoothed (0.5 m/z
Savitzky-Golay window, two cycles), and peaks were chosen (thresholds of 1.5 S/N, total possible
peaks at 1000, peak width 1.0 Da) by a batch processing macro written in FlexAnalysis software
(Version 4.3, Bruker Daltonics). Spectra normalization, using the Total Ion Count, and peak picking
were performed using Scils Lab software (version 2016b, Scil GmbH, Bremen, Germany).
2.10. LC-MS Data Analysis
Compartments resource was used to determine and map the identified protein localization and
get a confidence score [17]. The number of proteins within each subcellular localization was compared
between each extraction procedure using a Khi square test.
2.11. Back-Correlation of MALDI and LC-MS Data
Back-correlation was performed to link the peaks observed by MALDI-MSI with the identification
and label-free quantitation of proteins, using a 0.5% mass tolerance window. The correlation
between quantitation of proteins by label-free LC-MS/MS (variable LF) and peak intensities of
proteins observed by MALDI-MSI (variable MSI) was calculated using the formula: Correlation
index (LF,MSI) = ∑
(LF−LF) (MSI−MSI)√
∑(LF−LF)2 ∑(MSI−MSI)2
.
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3. Results
This study aimed at linking results from MALDI-MSI with potential peak identification and
relative label-free quantitation obtained by LC-MS/MS. For this, we developed a new workflow
combining MALDI-MSI on a muscle section, protein extraction ‘post-MSI’ from the same section,
their identification by LC-MS/MS and their relative quantitation by label-free analysis. At first,
we studied the impact of matrix deposition and laser ablation on protein extraction from tissue
sections. Then, we did a back-correlation of the m/z of the ‘post-MSI’ proteins to those of the proteins
detected by MALDI-MSI. This allowed us to correlate the label-free quantitation of proteins identified
by LC-MS/MS with their peak intensities observed by MALDI-MSI.
3.1. Protein Extraction Procedures and Identification
The first milestone of the workflow of MSI~LC-MS/MS-LF is the protein extraction, since
it is performed on matrix-coated sections after MALDI-MSI acquisition. To study the impact of
matrix deposition and laser ablation on protein extraction and identification, we compared the
identified proteins extracted on muscle tissue sections (‘On Tissue’) on sinapinic acid-coated sections
(‘SA-coated’), and on sinapinic acid-coated sections after MALDI-MSI acquisition (‘Post-MSI’).
The number of identified proteins in the 8 individuals was similar between the three conditions: 55, 63,
and 55 after ‘On Tissue’, ‘SA-coated’, and ‘Post-MSI’ extractions, respectively, corresponding to a total
of 72 proteins (Supplementary Data 1). In the present study, few proteins were specific to one condition,
or were identified in only two conditions, but more importantly, 42 of them were shared by the three
conditions (Figure 2). Therefore, regardless of the treatment, ‘On Tissue’, ‘SA-coated’ and ‘Post-MSI’
extractions resulted in a similar number of proteins. These results demonstrated that a bottom-up
approach is possible after in situ extraction, and that the matrix deposition and laser ablation have
no major impact on the number of identified proteins. Beyond the number of proteins identified in
each condition, we wanted to make sure that the common 42 identified proteins corresponded to
the most abundant peptides. The peptide spectrum match (PSM) can be used to evaluate the relative
abundance of a protein within a sample. For each protein, we calculated an abundance index (%PSMs)
as the percentage of the sum of PSMs for each condition (i.e., ‘On Tissue’, ‘SA-coated’, and ‘Post-MSI’)
(Table 2 and Supplementary Data 1). The sum of abundances of the 42 proteins identified within the
three conditions was 97% in ‘On Tissue’ extraction, 94% after ‘SA-coated’ extraction, and 94% after
‘Post-MSI’ extraction.
Table 2. List of identified proteins extracted on muscle tissue section (‘On Tissue’), on sinapinic
acid–coated section (‘SA-coated’), and on sinapinic acid-coated section after MALDI MSI acquisition
(‘Post-MSI’), expressed as the percentage of the sum of PSMs for each procedure condition.
References correspond to previous studies identifying proteins in a MALDI-MSI experiment.
The main cellular compartments are: C, cytosol; Ck, cytoskeleton; ER, endoplasmic reticulum;
ES, extracellular space; M, mitochondria; Mb, plasma membrane; N, nucleus.
Symbol Accession Description
Abundance Index (%)
References
Main Cellular
CompartmentOn Tissue SA-Coated After-MSI
ACTA1 P68133 Actin, α skeletal muscle 4.31 3.01 3.42 [9] Ck
ACTN2 P35609 A-actinin-2 0.31 0.82 1.37 [9] Ck
ATP5B P06576 ATP synthase subunit β,mitochondrial (Fragment) 0.15 0.16 0.12 [9] Mb
CA3 P07451 Carbonic anhydrase 3 5.69 1.49 0.62 [9] C
CKM P06732 Creatine kinase M-type 37.0 11.4 3.29 [9] C
DES P17661 Desmin 0.10 0.08 0.44 [9] Ck
ENO3 P06733 Enolase (Fragment) 3.49 1.14 1.12 [9] C
FABP3 P05413 Fatty acid-binding protein, heart 0.51 0.04 0.06 [9] C
FHL1 Q5JXI0 Four and a half LIM domainsprotein 1 (Fragment) 0.21 0.55 0.81 [9] N
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Table 2. Cont.
Symbol Accession Description
Abundance Index (%)
References
Main Cellular
CompartmentOn Tissue SA-Coated After-MSI
ALDOA P04075-H3BR68 Fructose-bisphosphatealdolase A (Fragment) 0.10 0.47 1.99 [9] C
ALDOC P09972 Fructose-bisphosphatealdolase C (Fragment) 0.05 0.39 0.06 [9] C
GAPDH P04406 Glyceraldehyde-3-phosphatedehydrogenase 0.97 1.45 0.12 [9] C
HSPB1 P04792 Heat shock protein β-1 0.10 0.59 0.12 [9] N
HSSPB7 C9J5A3-E9PN25 Heat shockprotein β-7 (Fragment) 0.46 0.31 0.12 [9] N
HBA1 P69905 Hemoglobin subunit α 0.26 2.11 0.56 [16] ES
HBB P68871 Hemoglobin subunit β 1.13 4.46 2.05 [16] ES
PYGM P11217-2 Isoform 2 of Glycogen phosphorylase,muscle form 1.38 0.51 0.12 [9] C
TRDX P10599-2 Isoform 2 of Thioredoxin 0.26 0.08 0.19 [17] C
TPI1 P60174-1
Isoform 2 of
Triosephosphate isomerase 10.51 1.25 0.25 [9,16] C
LDHA P00338-4
Isoform 4 of L-lactate
dehydrogenase A chain 0.05 0.16 0.06 [9] C
LDB3 O75112-6
Isoform 6 of LIM
domain-binding protein 3 0.05 0.59 0.99 [9] Ck
MB B0QYF8 Myoglobin (Fragment) 4.72 4.66 3.67 [9] C
MYBPC1 G3V1V7
Myosin binding protein C,
slow type, isoform CRA_e 0.05 0.23 0.19 [9] C
MYL1 P05976
Myosin light chain 1/3,
skeletal muscle isoform 5.84 6.73 1.86 [9] Ck
MYL3 P08590 Myosin light chain 3 1.18 2.47 1.86 [9] Ck
MYLPF Q96A32
Myosin regulatory light chain 2,
skeletal muscle isoform 0.56 1.57 0.68 [9] Ck
MYH1 P12882 Myosin-1 3.49 6.34 14.11 [9] Ck
MYH2 Q9UKX2 Myosin-2 4.41 8.26 15.79 [9] Ck
MYH4 Q9Y623 Myosin-4 2.36 1.68 0.19 [9] Ck
MYHCB P12883 Myosin-7 3.23 7.40 17.78 [9] Ck
NEB F8WCL5 Nebulin 0.05 0.04 0.19 [9] Ck
OR2T35 Q8NGX2 Olfactory receptor 2T35 0.10 0.08 0.06 Mb
PEBP1 P30086
Phosphatidylethanolamine-binding
protein 1 0.36 0.31 0.25 [9,15] C
PGAM2 P15259 Phosphoglycerate mutase 2 0.31 0.12 0.06 [9] C
PKM H3BQ34 Pyruvate kinase 0.05 0.27 0.44 [9] C
TTN Q8WZ42 Titin (Fragment) 0.05 0.12 1.31 [9] Ck
TPM1 P09493-H0YK20 Tropomyosin α-1 chain (Fragment) 0.77 6.03 5.22 [9] Ck
TPM3 P06753 Tropomyosin α-3 chain 0.10 4.39 4.29 [9] Ck
TPM2 P07951 Tropomyosin β chain 1.74 10.02 5.90 [9] Ck
TNNC2 P02585 Troponin C, skeletal muscle 0.36 0.94 0.44 [9] Ck
TNNI2 P48788 Troponin I, fast skeletal muscle 0.05 0.51 0.81 [9] Ck
TNNT3 C9JCA5
Troponin T, fast skeletal
muscle (Fragment) 0.05 0.90 0.93 [9] Ck
IFIT2 P09913
Interferon-induced protein with
tetratricopeptide repeats 2 0.15 0.04 [9] ER
IDH2 B4DFL2
Isocitrate dehydrogenase
[NADP] (fragment) 0.10 0.16 [9] M
KIDINS220 Q9ULH0-3
Isoform 3 of Kinase D-interacting
substrate of 220 kDa 0.05 0.04 Mb
PGM1 P36871 Phosphoglucomutase-1 1.49 0.08 [9] C
S100A1 P23297 Protein S100-A1 0.15 0.20 [9,16] ER
ALB P02768 Serum albumin 0.15 0.16 [9,15] ES
COX5A H3BRM5
Cytochrome c oxidase
subunit 5A, mitochondrial 0.05 0.06 [9] M
SOD2 B4E3K9-H7BYH4 Superoxide dismutase 0.15 0.12 [9] M
GSTP1 A8MX94 Glutathione S-transferase P 0.05 [9,15] C
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Table 2. Cont.
Symbol Accession Description
Abundance Index (%)
References
Main Cellular
CompartmentOn Tissue SA-Coated After-MSI
AKR1B15 C9JRZ8-2
Isoform 2 of Aldo-keto reductase
family 1 member B15 0.10 C
XPC Q01831-2
Isoform 2 of DNA repair protein
complementing XP-C cells 0.05 N
HEBP2 Q9Y5Z4-2 Isoform 2 of Heme-binding protein 2 0.10 [9] M
PGK1 B7Z7A9 Phosphoglycerate kinase 0.46 C
PFKM P08237
6-phosphofructokinase,
muscle type (Fragment) 0.04 0.06 [9] C
HSPB5 E9PR44-E9PNH7 A-crystallin B chain (Fragment) 0.23 0.37 [9] N
COL1A2 P08123 Collagen α-2(I) chain 0.04 0.06 [9] ES
HIST1H1T P22492 Histone H1t 0.12 0.12 [15,18] N
H2AFV A8MQC5 Histone H2A 0.04 0.06 [9] N
FNC Q14315-2 Isoform 2 of Filamin-C 0.04 0.25 [9] C
MYOZ1 Q9NP98 Myozenin-1 0.31 0.25 [9] N
SERCO1 B3KY17
Sarcoplasmic/endoplasmic reticulum
calcium ATPase 1 0.04 0.25 [9] Mb
TPM3 Q5VU72 Tropomyosin 3, isoform CRA_a 3.37 2.86 [9] Ck
TNNC1 P63316
Troponin C, slow skeletal and
cardiac muscles 0.31 0.68 [9] Ck
TNNI1 P19237 Troponin I, slow skeletal muscle 0.27 0.75 [9] Ck
CASQ1 P31415 Calsequestrin-1 0.08 [9] M
CSRP3 P50461 Cysteine and glycine-rich protein 3 0.12 [9] C
KIF15 Q9NS87-3 Isoform 3 of Kinesin-like protein KIF15 0.12 C
USMG5 Q96IX5
Up-regulated during skeletal muscle
growth protein 5 0.08 [9] M
UQCRB P14927 Cytochrome b-c1 complex subunit 7 0.06 [1] M
UBB J3QSA3 Ubiquitin (Fragment) 0.12 [9,15,16] N
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Although matrix deposition and laser ablation did not impact the number of identified 
proteins, we wanted to verify that these procedures did not result in preferential extraction from a 
specific cellular compartment. To achieve this point, we analyzed the results using the 
Compartments resource [14] which maps the proteins within the cell and gives a confidence score to 
the localization evidence. The results showed that in situ extraction led to the identification of 
proteins from the cytosol, cytoskeleton, nucleus, mitochondrion, endoplasmic reticulum, plasma 
membrane, and extracellular space (Figure 3). All proteins were classified according to their main 
cellular compartment, but some of them are described in the database as belonging to several 
cellular compartments (Supplementary Data 2). However, although the cellular repartition was 
qualitatively similar for proteins from ‘On tissue’, ‘SA-coated’ and ‘Post-MSI’ extracts, there were 
quantitative differences for some individual proteins. For the 42 proteins identified in the three 
extraction procedures, we compared the evolution of the abundance index to evaluate the 
proportion of proteins within each procedure. These revealed three groups: the first one 
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Figure 2. Venn diagram repr ti g the number of proteins d ntified on muscle tissue section
(‘On Ti sue’, red circle), on sinap nic acid–coated section (‘SA-coated’, yellow circle), nd after-MSI
acquisition (‘Post-MSI’, blue circle); 42 proteins were common to all conditions, 4 were only identified
in ‘SA-coated’ condition, 2 were only identified in ‘Post-MSI’ condition, 5 were only identified in
‘On-Tissue’ condition, 11 were common to ‘SA-coated’ (in green) and ‘Post-MSI’ conditions, 6 were
common to ‘SA-coated’ and ‘On-Tissue’ conditions (in orange), 2 were common to ‘Post-MSI’ and
‘On-Tissue’ conditions.
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Although matrix deposition and laser ablation did not impact the number of identified proteins,
we wanted to verify that these procedures did not result in preferential extraction from a specific
cellular compartment. To achieve this point, we analyzed the results using the Compartments
resource [14] which maps the proteins within the cell and gives a confidence score to the localization
evidence. The results showed that in situ extraction led to the identification of proteins from the cytosol,
cytoskeleton, nucleus, mitochondrion, endoplasmic reticulum, plasma membrane, and extracellular
space (Figure 3). All proteins were classified according to their main cellular compartment, but some
of them are described in the database as belonging to several cellular compartments (Supplementary
Data 2). However, although the cellular repartition was qualitatively similar for proteins from
‘On Tissue’, ‘SA-coated’ and ‘Post-MSI’ extracts, there were quantitative differences for some individual
proteins. For the 42 proteins identified in the three extraction procedures, we compared the evolution
of the abundance index to evaluate the proportion of proteins within each procedure. These revealed
three groups: the first one corresponded to the proteins showing a decreasing abundance index
during the extraction steps; the second one corresponded to the proteins showing an increasing
abundance index during the extraction steps; and the third one corresponded to the proteins
showing different kinds of patterns (Table 2, Figure 4). The first group included mainly cytosolic
proteins: carbonic anhydrase 3 (CA3); creatine kinase M-type (CKM); enolase (fragment) (ENO3);
fatty acid binding-protein, heart (FABP3); isoform 2 of glycogen phosphorylase, muscle form (PYGM);
isoform 2 of triose phosphate isomerase (TPI1); phosphatidylethanolamine-binding protein 1 (PEBP1);
phosphoglycerate mutase 2 (PGAM2). The second group included mainly structural proteins from
the cytoskeleton and contractile apparatus: α-actinin 2 (ACTN2); isoform 6 of LIM domain-binding
protein 3 (FHL1); myosin-1 (MYH1); myosin-2 (MYH2); myosin-7 (MYH7); titin (fragment) (TTN);
tropomyosin α-3 chain (TPM1); troponin I fast skeletal muscle (TNNI2); troponin T fast skeletal muscle
(fragment) (TNNT3). These results indicated that there was a lower abundance of cytosolic proteins
and a higher abundance of structural proteins within the extracts after matrix deposition and laser
ablation. Beside their subcellular location, other factors (such as their physicochemical properties)
might also be important for the extractability of proteins from the matrix layer.
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Figure 4. Representation of protein abundance index decreasing (A) and increasing (B) during the
three extraction procedures (i.e., ‘On Tissue’ in red; ‘SA-coated’ in yellow; and ‘Post-MSI’ in blue).
Protein identifications were compared to the databases MSiMass List [24] and MaTisse [13]
(Table 2). MSiMass List is a public database implemented by users who assign identities to the peaks
observed in their own experiment. MaTisse is a publically available database which compiles the
identifications obtained in top-down and bottom-up approaches after in situ protein extraction. Most of
our proteins were already described in a MALDI imaging experiment (Table 2). Among the 72 proteins
identified in ou experiment, only six were not describ d in these dat bases: Isoform 3 of kinesin-like
protein KIF 15 (KIF15); Isofo m 2 of aldo-keto reductase family 1 member B15 (ALDOC); Isoform 2 of
DNA repair protein complementing XP-C cells (XPC); Isoform 3 of kinase D-interacting substr t of
220 kDa (KIDINS220); Olfactory recept r 2T35 (OR2T35); Phosphoglycerate kinase (PGK1). This result
was independent of the extraction procedure as Isoform 2 of Aldo-keto reductase family 1 member B15
and Isoform 2 of DNA repair protein complementing XP-C cells were identified only on the ‘On Tissue’
section, Isoform 3 of Kinesin-like protein KIF15 only on the ‘SA-coated’ section, and Olfactory receptor
2T35 in the three procedures.
At last, it was important to determine how the ‘Post-MSI’ proteome is representative of the proteome
studied by ‘Muscle homogenate’ proteomic workflow, i.e., using direct muscle homogenization and
protein extraction. For this, we compared the identified proteins in both conditions (Supplementary
Data 3). From the 195 proteins identified with the ‘Muscle homogenate’ workflow, 46 were found in
the ‘Post-MSI’ proteome, and these 46 proteins accounted for 66% of the ‘Muscle homogenate’ PSMs.
Regression analysis indicated that for these 46 proteins, there was a positive correlation (r = 0.83,
p < 0.001) between their ‘Post-MSI’ and ‘Tissue Homogenate’ abundance indexes (%PSM).
3.2. Back-Correlation of the m/z of the Off-Tissue Identified Proteins to Those of the Proteins Detected
by MALDI-MSI
The second milestone of the MSI~LC-MS/MS-LF workflow is the back-correlation of the proteins
identified by LC-MS/MS to those detected by MALDI-MSI. Based on the idea from Maier et al. [13],
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that any MSI protein biomarker must be contained in the MALDI matrix layer to be detectable by the
mass spectrometer, back-correlation relies on matching m/z identified by LC-MS/MS to m/z detected
by MALDI-MSI.
MALDI spectra were recorded from 2000 to 20,000 m/z, and a mean spectrum was calculated for
each MALDI-MSI sequence. Mean spectra had a similar global pattern, and showed peaks with higher
intensity at low mass range (Figure 5). We succeeded in linking protein identification to nine peaks
observed by MALDI-MSI, using a mass tolerance interval set at 0.5% (Figure 5; Supplementary
Data 4): superoxide dismutase (m/z 6776); cytochrome c oxidase subunit 5A, mitochondrial
(m/z 7802); isoform 4 of L-lactate dehydrogenase A chain (m/z 7903); tropomyosin α-1 chain
(fragment) (m/z 11051); α-crystallin B chain (fragment) (m/z 11,987); heat shock protein β-7 (fragment)
(m/z 13,645); fructose-biphosphate aldolase A (fragment) (m/z 14,981); myoglobin (fragment)
(m/z 15,970); and four and a half LIM domain protein 1 (fragment) (m/z 16,085).
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The label-free strategy was then applied to compare quantitation of ‘Post-MSI’ proteins extracted
in situ and their MALDI-MSI peak intensities. The analysis resulted in the quantitation of 35 proteins
from the 57 identified in ‘Post-MSI’ (Supplementary Data 4), and gave a relative quantitation for
all proteins linked to a peak observed by MALDI-MSI. We calculated the correlation between the
label-free quantitation of ‘Post-MSI’ proteins and the peak intensity observed by MALDI-MSI (Figure 5).
Except for α-crystallin B chain (fragment), which showed a correlation index of 0.21, we observed
good correlations between both approaches: 0.36 for heat shock protein β-7 (fragment) and 0.42 for
four-and-a-half LIM domain protein 1 (fragment); 0.50 for tropomyosin α-1 chain (fragment), 0.57 for
cytochrome c oxidase subunit 5A, mitochondrial; 0.58 for both fructose-biphosphate aldolase C
(fragment) and myoglobin (fragment); 0.75 for superoxide dismutase; and 0.93 for isoform 4 of
L-lactate dehydrogenase A chain (with a significant result for the last two). These results demonstrated
the relevance of the MSI~LC-MS/MS-LF workflow as a proof-of-concept, which aimed at linking
MALDI-MSI peak intensities with label-free quantitation. To the best of our knowledge, this is the first
time that such a study has been presented.
4. Discussion
At first, we studied the impact of matrix deposition and laser ablation on protein extraction from
tissue sections. The number of proteins identified after extraction from tissue sections is consistent
with what was found on sections of ocular lens where 50 to 100 proteins were identified [12],
and after in situ hydrogel-based protein digestion on brain sections [18] where over 50 proteins
were identified. The number of identified proteins is less than the mean number of proteins identified
by Maier et al. [13], but they used tissue sections of about 5 cm2, which is much larger than the ones
used in the present work (10 mm2, see Experimental Section). Franck et al. [15] explained that the
area of the tissue section is linked to the number of proteins identified and recommended to analyze
sections of similar sizes to prevent any variations in protein number.
Mapping the main cellular compartment for each identified protein suggested an apparent
homogeneity of the three extraction procedures: the statistical tests (Khi square test, Supplementary
Data 2) indicated that none of the extraction procedures changed the qualitative distribution of
the proteins between the different cellular compartments. Moreover, the distribution is consistent
with that observed by Maier et al. [13] after in situ extraction and the bottom-up strategy.
In addition, the repartition of proteins according to their cellular compartment is consistent with
the characterization of the human vastus lateralis muscle by a global proteomic study [23]. This study
succeeded in linking protein identification to nine peaks observed by MALDI-MSI. In terms of the ratio
between detected ions and ions linked with identification, this is consistent with what was achieved
on peptide back-correlation by Minerva et al. [25]. They identified 46 peptides of the 136 detected with
MALDI-MSI, and for 31 of these, a back-correlation with LC-MS was possible and revealed a similar
peak intensity ratio for 18 peptides.
Thanks to these results, we are able to determine the localization of these proteins, and to compare
their intensities between different muscle sections to study various biological phenomena. Indeed,
the proteins resulting from this analysis are known to be involved in several biological mechanisms
occurring in skeletal muscle: aging [26–32], atrophy and myopathy [33–35] or association with
non-obese type 2 diabetes [36].
5. Conclusions
The purpose of this proof-of-concept study was to evaluate the power of MALDI-MSI for relative
quantitation of proteins between experimental conditions. The MSI~LC-MS/MS-LF workflow allowed
us to use only one 10-µm-thick muscle section to perform both MALDI mass spectrometry imaging
and protein extraction, with further back-correlation of label-free quantitation with the peak intensities
observed in MALDI-MSI. This is critical for rare human biopsies. In a biological study, it should be
recommended to perform analysis in triplicate to improve the accuracy of the label-free quantitation.
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Despite the use of low resolution for protein identification, we linked nine MALDI-MSI peaks to the
label-free quantitation of proteins identified as biomarkers of various skeletal muscle physiological
studies. We believe that this proof-of-concept could increase the potential application of MALDI-MSI
of proteins in the study of skeletal muscle, and that it would be improved by the use of high resolution
to increase the number of back-correlations between MALDI-MSI and protein identifications.
Supplementary Materials: The supplementary materials are available online at www.mdpi.com/2227-7382/4/
4/32/s1.
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Abbreviations
MALDI Matrix Assisted Laser Desorption Ionization
LC-MS Liquid Chromatography – Mass Spectrometry
LF Label-Free
MSI Mass Spectrometry Imaging
ISD In-Source Decay
SA Sinapinic Acid
ACN Acetonitrile
TFA Trifluoroacetic Acid
PSM Peptide Spectrum Match
C Cytosol
Ck Cytoskeleton
ER Endoplasmic Reticulum
ES Extracellular Space
M Mitochondria
Mb Plasma Membrane
N Nucleus
References
1. Caprioli, R.M.; Farmer, T.B.; Gile, J. Molecular imaging of biological samples: Localization of peptides and
proteins using MALDI-TOF MS. Anal. Chem. 1997, 69, 4751–4760. [CrossRef] [PubMed]
2. Gueugneau, M.; Coudy-Gandilhon, C.; Théron, L.; Meunier, B.; Barboiron, C.; Combaret, L.; Taillandier, D.;
Polge, C.; Attaix, D.; Picard, B.; et al. Skeletal muscle lipid content and oxidative activity in relation to
muscle fiber type in aging and metabolic syndrome. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2015, 70, 566–576.
[CrossRef] [PubMed]
3. Gueugneau, M.; Coudy-Gandilhon, C.; Gourbeyre, O.; Chambon, C.; Combaret, L.; Polge, C.; Taillandier, D.;
Attaix, D.; Friguet, B.; Maier, A.B.; et al. Proteomics of muscle chronological ageing in post-menopausal
women. BMC Genom. 2014. [CrossRef] [PubMed]
4. Theron, L.; Gueugneau, M.; Coudy, C.; Viala, D.; Bijlsma, A.; Butler-Browne, G.; Maier, A.; Bechet, D.;
Chambon, C. Label-free quantitative protein profiling of vastus lateralis muscle during human aging.
Mol. Cell. Proteom. 2013, 13, 283–294. [CrossRef] [PubMed]
5. Mascini, N.E.; Heeren, R.M.A. Protein identification in mass-spectrometry imaging. Trends Anal. Chem. 2012,
40, 28–37. [CrossRef]
6. Groseclose, M.R.; Andersson, M.; Hardesty, W.M.; Caprioli, R.M. Identification of proteins directly from
tissue: In situ tryptic digestions coupled with imaging mass spectrometry. J. Mass Spectrom. 2007, 42, 254–262.
[CrossRef] [PubMed]
Proteomes 2016, 4, 32 15 of 16
7. Goodwin, R.J.A. Sample preparation for mass spectrometry imaging: Small mistakes can lead to big
consequences. J. Proteom. 2012, 75, 4893–4911. [CrossRef] [PubMed]
8. Chughtai, K.; Heeren, R.M.A. Mass spectrometric imaging for biomedical tissue analysis. Chem. Rev. 2010,
110, 3237–3277. [CrossRef] [PubMed]
9. Debois, D.; Bertrand, V.; Quinton, L.; De Pauw-Gillet, M.C.; De Pauw, E. MALDI-in source decay applied
to mass spectrometry imaging: A new tool for protein identification. Anal. Chem. 2010, 82, 4036–4045.
[CrossRef] [PubMed]
10. Hardouin, J. Protein sequence information by matrix-assisted laser desorption/ionization in-source decay
mass spectrometry. Mass Spectrom. Rev. 2007, 26, 672–682. [CrossRef] [PubMed]
11. Quanico, J.; Franck, J.; Dauly, C.; Strupat, K.; Dupuy, J.; Day, R.; Salzet, M.; Fournier, I.; Wisztorski, M.
Development of Liquid Microjunction Extraction Strategy for Improving Protein Identification from
Tissue Sections. J. Proteom. 2013, 79, 200–218. [CrossRef] [PubMed]
12. Schey, K.L.; Anderson, D.M.; Rose, K.L. Spatially-directed protein identification from tissue sections by
top-down LC-MS/MS with electron transfer dissociation. Anal. Chem. 2013, 85, 6767–6774. [CrossRef]
[PubMed]
13. Maier, S.K.; Hahne, H.; Gholami, A.M.; Balluff, B.; Meding, S.; Schoene, C.; Walch, A.K.; Kuster, B.
Comprehensive identification of proteins from MALDI imaging. Mol. Cell. Proteom. 2013, 12, 2901–2910.
[CrossRef] [PubMed]
14. Spraggins, J.M.; Rizzo, D.R.; Moore, J.L.; Rose, K.L.; Hammer, N.D.; Skaar, E.P.; Caprioli, R.M. MALDI FTICR
IMS of Intact Proteins: Using Mass Accuracy to Link Protein Images with Proteomics Data. J. Am. Soc.
Mass Spectrom. 2015, 26, 974–985. [CrossRef] [PubMed]
15. Ferreira Aquino, P.; Borges Lima, D.; De Saldanha da Gama Fischer, J.; Donadelli Melani, F.C.S.; Nogueira, R.;
Chalub, S.R.S.; Soares, E.R.; Barbosa, V.C.; Domont, G.B.; Carvalho, P.C. Exploring the Proteomic Landscape
of a Gastric Cancer Biopsy with the Shotgun Imaging Analyzer. J. Proteome Res. 2014, 13, 314–320. [CrossRef]
[PubMed]
16. Franck, J.; Quanico, J.; Wisztorski, M.; Day, R.; Salzet, M.; Fournier, I. Quantification-based mass spectrometry
imaging of proteins by parafilm assisted microdissection. Anal. Chem. 2013, 85, 8127–8134. [CrossRef]
[PubMed]
17. Binder, J.X.; Pletscher-Frankild, S.; Tsafou, K.; Stolte, C.; O’Donoghue, S.I.; Schneider, R.; Jensen, L.J.
COMPARTMENTS: Unification and visualization of protein subcellular localization evidence. Database 2014.
[CrossRef] [PubMed]
18. Nicklay, J.J.; Harris, G.A.; Schey, K.L.; Caprioli, R.M. MALDI imaging and in situ identification of integral
membrane proteins from rat brain tissue sections. Anal. Chem. 2013, 85, 7191–7196. [CrossRef] [PubMed]
19. Chaurand, P.; Fouchecourt, S.; Dague, B.B.; Xu, B.J.; Reyzer, M.L.; Orgebin-Crist, M.C.; Caprioli, R.M.
Profiling and imaging proteins in the mouse epididymis by imaging mass spectrometry. Proteomics 2003, 3,
2221–2239. [CrossRef] [PubMed]
20. Hardesty, W.M.; Kelley, M.C.; Mi, D.; Low, R.L.; Caprioli, R.M. Protein signatures for survival and recurrence
in metastatic melanoma. J. Proteom. 2011, 74, 1002–1014. [CrossRef] [PubMed]
21. Lagarrigue, M.; Alexandrov, T.; Dieuset, G.; Perrin, A.; Lavigne, R.; Baulac, S.; Thiele, H.; Martin, B.;
Pineau, C. New analysis workflow for MALDI imaging mass spectrometry: Application to the discovery
and identification of potential markers of childhood absence epilepsy. J. Proteome Res. 2012, 11, 5453–5463.
[CrossRef] [PubMed]
22. Harris, G.A.; Nicklay, J.J.; Caprioli, R.M. Localized in situ hydrogel-mediated protein digestion and extraction
technique for on-tissue analysis. Anal. Chem. 2013, 85, 2717–2723. [CrossRef] [PubMed]
23. Hojlund, K.; Yi, Z.; Zwang, H.; Bowen, B.; Lefort, N.; Flynn, C.R.; Langlais, P.; Weintraub, S.T.; Mandarino, L.J.
Characterization of the human skeletal muscle proteome by one-dimensional gel electrophoresis and
HPLC-ESI-MS/MS. Mol. Cell. Proteom. 2008, 7, 257–267. [CrossRef] [PubMed]
24. McDonnell, L.A.; Walch, A.; Stoeckli, M.; Corthals, G.L. MSiMass List: A Public Database of Identifications
for Protein MALDI MS Imaging. J. Proteome Res. 2013, 13, 1138–1142. [CrossRef] [PubMed]
25. Minerva, L.; Boonen, K.; Menschaert, G.; Landuyt, B.; Baggerman, G.; Arckens, L. Linking mass spectrometric
imaging and traditional peptidomics: A validation in the obese mouse model. Anal. Chem. 2011, 83,
7682–7691. [CrossRef] [PubMed]
Proteomes 2016, 4, 32 16 of 16
26. Kanski, J.; Alterman, M.A.; Schöneich, C. Proteomic identification of age-dependent protein nitration in rat
skeletal muscle. Free Radic. Biol. Med. 2003, 35, 1229–1239. [CrossRef]
27. Piec, I.; Listrat, A.; Alliot, J.; Chambon, C.; Taylor, R.G.; Bechet, D. Differential proteome analysis of aging in
rat skeletal muscle. FASEB J. 2005, 19, 1143–1145. [CrossRef] [PubMed]
28. Doran, P.; Gannon, J.; O’Connell, K.; Ohlendieck, K. Aging skeletal muscle shows a drastic increase in the
small heat shock proteins αB-crystallin/HspB5 and cvHsp/HspB7. Eur. J. Cell. Biol. 2007, 86, 629–640.
[CrossRef] [PubMed]
29. Doran, P.; O’Connell, K.; Gannon, J.; Kavanagh, M.; Ohlendieck, K. Opposite pathobiochemical fate of
pyruvate kinase and adenylate kinase in aged rat skeletal muscle as revealed by proteomic DIGE analysis.
Proteomics 2008, 8, 364–377. [CrossRef] [PubMed]
30. Gannon, J.; Staunton, L.; O’Connell, K.; Doran, P.; Ohlendieck, K. Phosphoproteomic analysis of aged skeletal
muscle. Int. J. Mol. Med. 2008, 22, 33–42. [CrossRef] [PubMed]
31. Lombardi, A.; Silvestri, E.; Cioffi, F.; Senese, R.; Lanni, A.; Goblia, F.; De Lange, P.; Moreno, M. Defining the
trascriptomic and proteomic profiles of rat ageing skeletal muscle by the use of a cDNA array, 2D- and Blue
native-PAGE approach. J. Proteom. 2009, 72, 708–721. [CrossRef] [PubMed]
32. McDonagh, B.; Sakellariou, G.K.; Jackson, M.J. Application of redox proteomics to skeletal muscle aging and
exercise. Biochem. Soc. Trans. 2014, 42, 965–970. [CrossRef] [PubMed]
33. Jia, L.; Xu, L.; Jiang, M.; Gu, Y.; Zhang, Z. Protein abnormality in denervated skeletal muscles from patients
with brachial injury. Microsurgery 2005, 25, 316–321. [CrossRef] [PubMed]
34. Kramerova, I.; Kudryashova, E.; Wu, B.; Germain, S.; Vandenborne, K.; Romain, N.; Haller, R.G.;
Verity, M.A.; Spencer, M.J. Mitochondrial abnormalities, energy deficit and oxidative stress are features of
calpain 3 deficiency in skeletal muscle. Hum. Mol. Gen. 2009, 18, 3194–3205. [CrossRef] [PubMed]
35. Sato, Y.; Shimizu, M.; Mizunoya, W.; Wariishi, H.; Tatsumi, R.; Buchman, V.L.; Ikeuchi, Y. Differential
Expression of Sarcoplasmic and Myofibrillar Proteins of Rat Soleus Muscle during Denervation Atrophy.
Biosci. Biotech. Biochem. 2009, 73, 1748–1756. [CrossRef] [PubMed]
36. Maerkens, A.; Kley, R.A.; Olive, M.; Theis, V.; van der Ven, P.F.M.; Reimann, J.; Milting, H.; Schreiner, A.;
Uszkoreit, J.; Eisenacher, M.; et al. Differential proteomic analysis of abnormal intramyoplasmic aggregates
in desminopathy. J. Proteom. 2013, 90, 14–27. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
